BICX BioCorrx Inc

BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th

BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th

ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it will be presenting at LD Micro’s 14th annual Main Event on Tuesday, October 12, 2021, at 1:30 PM PT/4:30 PM ET at the Luxe Sunset Bel-Air in Los Angeles. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will present at the conference.

Event: LD Micro Main Event

Date: Tuesday, October 12, 2021

Time: 1:30 PM PT/4:30 PM ET

Register to watch the virtual presentation .

Summary of LD Micro Main Event (XIV)

The 2021 LD Micro Main Event will be held at the Luxe Sunset Bel-Air in Los Angeles from Tuesday, October 12th to Thursday, October 14th. 

The festivities run from 8 AM PT - 5:30 PM PT on the 12th and 13th with a morning session on the 14th.

This three-day investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in person. 

For more info, please contact 

About LD Micro 

LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit  for more information on UnCraveRx®. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit .

BioCorRx Inc.



714-462-4880



Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304



EN
29/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE

BioCorRx Reports Business Update for the Second Quarter of 2024

BioCorRx Reports Business Update for the Second Quarter of 2024 ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to...

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurologi...

 PRESS RELEASE

BioCorRx Reports Business Update for 2023

BioCorRx Reports Business Update for 2023 ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid ...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch